THE LONG DAWN

Dispatches / Rare disease

No life too rare

First treatment approved for the neurological symptoms of type 3 Gaucher disease

A small molecule that crosses the blood-brain barrier, reaching where earlier treatments could not.

ApprovedRegulator decision

What happened

  • The FDA approved Infilbray (venglustat, Sanofi's Genzyme) tablets on 18 Nov 2026 for the neurological symptoms of type 3 Gaucher disease in people weighing at least 15 kg.
  • In a randomized, double-blind study of 43 patients aged 12 and over, people on venglustat did better at week 52 on a combined measure of coordination and thinking than people on enzyme replacement therapy.
  • Enzyme replacement treats the body but does not reach the brain; venglustat does.

What we don't know yet

  • The FDA lists serious psychiatric risks, including suicidal thoughts and behaviour, and possible eye and pregnancy risks from animal studies.
  • 43 patients is a small trial, typical for a rare disease.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.